The management of hypercalcemia of malignancy
Author:
- 1 March 1995
- journal article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 3 (2) , 123-129
Abstract
Hypercalcemia (HCM) occurs in 10–15% of all malignancies, predominantly in patients with solid tumors. This metabolic complication leads to significant morbidity and impairment of quality of life. Recent insights into the pathophysiology of HCM include an understanding of the role of parathyroid-hormone-related peptide and several cytokines secreted by tumors. The osteoclast plays a central role as the final common pathway through which these hormones and cytokines act to cause bone lysis. These findings have led to the development of new treatment strategies. Foremost among these has been the introduction of agents such as the newer bisphosphonates and gallium nitrate, which are potent inhibitors of osteoclast-mediated bone resorption. The clinician can now choose from an array of therapeutic approaches based on a consideration of the mechanisms of action, individual clinical circumstances, efficacy, toxicities and costs of available agents. In addition to their use in the management of HCM, non-toxic drugs that effectively inhibit osteoclast function, such as the bisphosphonates, are playing an emerging role in the palliative treatment of the more common clinical problems of painful lytic bone metastases and osteoporosis.Keywords
This publication has 45 references indexed in Scilit:
- Circulating PTHrP concentrations in tumor-induced hypercalcemia: Influence on the response to bisphosphonate and changes after therapyJournal of Bone and Mineral Research, 1993
- Newer Agents for the Treatment of MalignantHypercalcemiaThe American Journal of the Medical Sciences, 1993
- Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemiaPostgraduate Medical Journal, 1992
- Disodium Pamidronate Versus Mithramycin in the Management of Tumour-Associated HypercalcemiaActa Oncologica, 1992
- Malignancy Hypercalcemia: Evaluation of Parathyroid Function and Response to TreatmentThe American Journal of the Medical Sciences, 1991
- Humoral Hypercalcemia of CancerNew England Journal of Medicine, 1988
- THE PATHOGENESIS OF HUMORAL HYPERCALCAEMIA OF MALIGNANCYThe Lancet, 1987
- Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.Journal of Clinical Investigation, 1985
- PRIMARY HYPERPARATHYROIDISM: CHANGES IN THE PATTERN OF CLINICAL PRESENTATIONThe Lancet, 1980
- BREAST-CANCER OSTEOLYSIS, BONE METASTASES, AND ANTI-OSTEOLYTIC EFFECT OF ASPIRINThe Lancet, 1976